Tempus AI Inc. infringed five Guardant Health Inc. patents to create copy-cat diagnostic DNA tests, according to a new federal lawsuit.
The market success of Tempus’s tests derives from its unauthorized use of Guardant’s “groundbreaking” cancer diagnostics patents, Guardant said Tuesday in a complaint filed in the US District Court for the District of Delaware.
Tempus filed for an initial public offering on May 20 and noted that it could be subject to claims of patent infringement, mentioning other litigation involving Guardant in its S-1 filing with the US Securities and Exchange Commission. Tempus also said in the filing it’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.